# The Role of PKC Activation in the Immune-inflammatory Mechanism of Major Depressive Depression

> **NCT04156425** · NA · UNKNOWN · sponsor: **Shanghai Mental Health Center** · enrollment: 180 (estimated)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Escitalopram+golimumab
- **DIETARY_SUPPLEMENT:** Escitalopram+Calcium Tablet
- **DRUG:** Escitalopram

## Key facts

- **NCT ID:** NCT04156425
- **Lead sponsor:** Shanghai Mental Health Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2020-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04156425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04156425, "The Role of PKC Activation in the Immune-inflammatory Mechanism of Major Depressive Depression". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04156425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*